Tacrolimus reversibly reduces insulin secretion, induces insulin resistance, and causes islet cell damage in rats

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 7, 2014, Pages 620-627

  Xu, Chun ^a   Niu, Yu Jian ^a   Liu, Xiao Jun ^a   Teng, Ya Qin ^b   Li, Chun Feng ^c   Wang, Hong Yu ^a   Yin, Jun Ping ^d   Wang, Le Tian ^a   Shen, Zhong Yang ^a  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c Chinese Medical Multimedia Press Co Ltd   (China)

^d Clinical Laboratory Minmetals Hanxing Staff General Hospital   (China)

Author keywords

Diabetes meliitus; Insulin resistance; Insulin secretion; Reversibility; Tacrolimus

Indexed keywords

GLUCOSE; INSULIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MALE; NONHUMAN; PANCREAS ISLET CELL; RAT; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 84903945354     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202090     Document Type: Article

References (29)

1. Tarantino G, Pahtuero G, Polichetti G, Perfetti A, Sabbatini M, Basile V, Kadilli I, Federico S, Capone D. Long- Term assessment of plasma lipids in transplant recipients treated with tacrolimus in relation to fatty liver. Int J Immunopathol Pharmacol. 2010; 23: 1303-1308. PubMed.
2. CLTR. 2010 Annual Scientific Report. CLTR, China. http://www.cltr.org.
3. Bonato V, Caialdo D. Delta F, Carmellini M Diagnosis and approach to posttransplant diabetes. Cun- Diab Rep. 2009; 9: 317-323. CrossRef PubMed.
4. Shah T, Kasravi A, Huang E, Hayashi R, Young B, Cho YW: Bunnapradist S. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation. 2006; 82: 1673-1676. CrossRef PubMed. (Pubitemid 46035650)
5. Kumar N, Mariat C, Delahousse M, Lefranqoia N, DantaI J, Benhamou P. New onset diabetes mel- litus incidence and risk factors in kidney transplantation: results of the observational cross-sectional study diapason. Transplant Proc. 2006; 38: 2295-2297. CrossRef PubMed. (Pubitemid 46068531)
6. Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, Nam CM, Aim CW, Cha BS, Kim SI, Lee HC Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care. 2007; 30: 609-615. CrossRef PubMed.
7. Lerut J, Mathys J, Verbaandert C, Talpe S, Ciccarelli O, Lemaire J, Bonaccorsi-Riani E, Vanthuyne V, Hetsch N, Roggen F, Reyck CD, Goffette P, Latinne D, Orlando G, Rahier J, Sempowc C, Wallemacq P, Laterre PF, Gianelh P. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg. 2008; 248: 956-967. CrossRef PubMed.
8. Cho YM, Park KS, Jung US, Jean HJ, Aim C, Ha J, Kim SJ, Rhee BD, Kim SY, Lee HK. High inci-dence of tacrolimus- Associated posttransplantation diabetes in the Korean renal allograft recipi-ents according to American Diabetes Association criteria. Diabetes Care. 2003; 26: 1123-1128. CrossRef PubMed. (Pubitemid 36929259)
9. Larsen JL, Bennett RG, Burkman T, Ramirez AL, Yamamoto S, Gnlizia J, Radio S, HomeI FG. Ta-crolimus and sirolimus cause insulin resistance in normal sprague dawley rats. Transplantation. 2006; 82: 466-470. CrossRef PubMed. (Pubitemid 44290251)
10. Wyzgal J., Paezek L, Sanko-ResmerJ, Ciszek M, Nowak M, Rowinski W, Szmidt J, Durlik M, Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. Ann Transplant. 2007; 12: 26-29. PubMed.
11. Oetjen E, Baun D, Beimesche S, Krause D, Cierny I, BlumeR, Dickel C, Wehner S, Knepel W. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol. 2003; 63: 1289-1295. CrossRef PubMed. (Pubitemid 36627223)
12. Radii RG, Fujimoto S, Mukai E, Takehiro M, Shimono D, Nahe K, Shimodahira M, Kominato R, Aramaki Y, Nishi Y, Funakoshi S, Yamada Y, Seino Y., Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing gluco- kinase activity. Am J Physiol Endocrinol Metab. 2005; 288: E365-E371. CrossRef PubMed. (Pubitemid 40110645)
13. Rostamheigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmarm YW, Anderson JM, Schimke JM, Nair KS, Eherhardt NL, Kudva YC. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. Transplantation. 2011; 91: 615-623. CrossRef PubMed.
14. Li QY, Li F, Sun JH, Chi YY, Yin HS, Liu SQ, Met YH. Mechanisms of diabetes mellitus induced with FK506 in SD rats models. Immunopharmacol lmmunotoxicol. 2009; 31: 675-681. CrossRef PubMed.
15. Drachenherg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimifriou JC, Islet cell damage associated with tacrolimus and cyclosporine: morphological fea- Tures in pancreas allograft biopsies and clinical correlation. Transplantation. 1999; 68: 396-402. CrossRef PubMed. (Pubitemid 29384108)
16. Hernandez-Fisac I, Pizarro-Delgado J, Calle C, Marques M, Sanchez A, Barrientos A. Tamarit- Rodriguez J. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. Am J Transplant. 2007; 7; 2455-2462. CrossRef PubMed. (Pubitemid 47561596)
17. Shivaswamy V, McClure M, Passer J, Frahm C, Ochsner L, Erickson J, Bennett RG, Hamel FG, Larsen JL. Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague- dawley rats. Endocrine. 2010; 37: 489-496. CrossRef PubMed.
18. Shapiro R, Scantlebury I P. Jordan ML, Vivas C, Gritsch HA, McCauley J, Fung JJ. Hakala TR, Simmons RL, Starzl TE. Reversibility of tacrolim-us-induced posttransplant diabetes: An illustrative case and review of the literature. Transplant Proc. 1997; 29: 2737-2738. CrossRef PubMed. (Pubitemid 27383033)
19. Filler G, Neuschulz I, Vollmer I, Amendt P, Hocher B. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant. 2000: 15: 867-871. CrossRef PubMed. (Pubitemid 30312009)
20. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27: 1487-1495. CrossRef PubMed. (Pubitemid 38680001)
21. Li GW, Pan XR. [A new insulin-sensitivity index for the population-based study]. Zhonghua Nei Ke Za Zhi. 1993; 32: 656-660. PubMcd.
22. Chen KJ, Tang QY. Clinical application of FK506 in renal transplantation. Hebei Med. 2005; 11: 626-628.
23. Nassar CA, Nassar PO, Andia DC, Guimaraes MR, Pepato MT, Spolidorio LC. Biochemical evaluation of glycemic levels of long- Term tacrolimus therapy in rats. Braz Oral Res. 2007; 21: 293-297. CrossRef PubMed.
24. Wang JH, Liang TB, Zheng SS, Qin YS, Xu SG, Li YB. Effects of tacrolimus on insulin receptors in rat hepatocytie membrane. J Clin Surg. 2006; 14: 291-293.
25. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenhuttei BH, Van Hoqff JP Influence of ta-crolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol. 2001; 12: 583-588. PubMed. (Pubitemid 32180028)
26. Plaumann S, Blume R, Borchers S, Steinfelder HJ, Knepel W, Oetjen E. Activation of the dual-leucine- zippcr-bearing kinase and induction of beta-cell apoptosis by the immunosuppressive drug cyclosporin A. Mol Pharmacol. 2008; 73: 652-659. CrossRef PubMed. (Pubitemid 351397870)
27. Dumortier J, Bernard S, Bouffard Y, Boillot O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl. 2006; 12: 659-664. CrossRef PubMed.
28. Ghisdal L, Bouchta NB, Breeders N, Crenier L, Hoang AD, Abramowicz D, Hissing KM. Conver-sion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: A single-centre experience in renal transplanted patients and review of the literature. Transpl Int. 2008; 21: 146-151. PubMed.
29. Lorho R, Hardwigsen J, Dumortier J, Pageaux GP, Ditrand F, Bizollon T, Blanc AS, Di Giambattista F, Duvoux C. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study. Clin Res Hepatol Gastroenterol. 2011; 35: 482-488. PubMed.